BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

997 related articles for article (PubMed ID: 16084657)

  • 1. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
    Wang HY; Friedman E; Olmstead MC; Burns LH
    Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
    Xu H; Wang X; Wang J; Rothman RB
    Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
    Wang D; Raehal KM; Lin ET; Lowery JJ; Kieffer BL; Bilsky EJ; Sadée W
    J Pharmacol Exp Ther; 2004 Feb; 308(2):512-20. PubMed ID: 14600246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
    Liu JG; Prather PL
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
    Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling.
    Szücs M; Boda K; Gintzler AR
    J Pharmacol Exp Ther; 2004 Jul; 310(1):256-62. PubMed ID: 14996951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
    Puttfarcken PS; Werling LL; Cox BM
    Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ontogeny of mu opiate tolerance and dependence in the rat: antinociceptive and biochemical studies.
    Windh RT; Little PJ; Kuhn CM
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1361-74. PubMed ID: 7791109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic antidepressant treatment causes a selective reduction of mu-opioid receptor binding and functional coupling to G Proteins in the amygdala of fawn-hooded rats.
    Chen F; Lawrence AJ
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1020-6. PubMed ID: 15121763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
    Liu JG; Prather PL
    Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mu-Opioid receptors inhibit dopamine-stimulated activity of type V adenylyl cyclase but enhance dopamine-stimulated activity of type VII adenylyl cyclase.
    Yoshimura M; Ikeda H; Tabakoff B
    Mol Pharmacol; 1996 Jul; 50(1):43-51. PubMed ID: 8700117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chronic ethanol and withdrawal on the mu-opioid receptor- and 5-Hydroxytryptamine(1A) receptor-stimulated binding of [(35)S]Guanosine-5'-O-(3-thio)triphosphate in the fawn-hooded rat brain: A quantitative autoradiography study.
    Chen F; Lawrence AJ
    J Pharmacol Exp Ther; 2000 Apr; 293(1):159-65. PubMed ID: 10734165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic morphine treatment increases stimulatory beta-2 adrenoceptor signaling in A431 cells stably expressing the mu opioid receptor.
    Ammer H; Schulz R
    J Pharmacol Exp Ther; 1997 Jan; 280(1):512-20. PubMed ID: 8996236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic morphine augments G(beta)(gamma)/Gs(alpha) stimulation of adenylyl cyclase: relevance to opioid tolerance.
    Chakrabarti S; Rivera M; Yan SZ; Tang WJ; Gintzler AR
    Mol Pharmacol; 1998 Oct; 54(4):655-62. PubMed ID: 9765508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor.
    Xu H; Lu YF; Rothman RB
    Synapse; 2003 Jan; 47(1):1-9. PubMed ID: 12422367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenylyl cyclase supersensitivity in opioid-withdrawn NG108-15 hybrid cells requires Gs but is not mediated by the Gsalpha subunit.
    Ammer H; Schulz R
    J Pharmacol Exp Ther; 1998 Aug; 286(2):855-62. PubMed ID: 9694942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of mu opioid receptor binding and G protein coupling in rat hypothalamus, spinal cord, and primary afferent neurons during inflammatory pain.
    Shaqura MA; Zöllner C; Mousa SA; Stein C; Schäfer M
    J Pharmacol Exp Ther; 2004 Feb; 308(2):712-8. PubMed ID: 14593084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous intrathecal opioid treatment abolishes the regulatory effects of magnesium and guanine nucleotides on mu opioid receptor binding in rat spinal membranes.
    Wong CS; Su YF; Watkins WD; Chang KJ
    J Pharmacol Exp Ther; 1992 Jul; 262(1):317-26. PubMed ID: 1320689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand-selective activation of mu-oid receptor: demonstrated with deletion and single amino acid mutations of third intracellular loop domain.
    Chaipatikul V; Loh HH; Law PY
    J Pharmacol Exp Ther; 2003 Jun; 305(3):909-18. PubMed ID: 12626655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.